Drug Information

Drug General Information
Drug ID
D0LX8D
Former ID
DCL000478
Drug Name
AZD6918
Indication Advanced solid malignancies [ICD9: 140-199, 140-239, 210-229; ICD10:D10-D36, D3A] Discontinued in Phase 1 [548789]
Company
AstraZeneca
Target and Pathway
Target(s) Neurotrophic tyrosine kinase receptor 1 Target Info Inhibitor [550288]
KEGG Pathway MAPK signaling pathway
Endocytosis
Apoptosis
Neurotrophin signaling pathway
Inflammatory mediator regulation of TRP channels
Pathways in cancer
Transcriptional misregulation in cancer
Thyroid cancer
Central carbon metabolism in cancer
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Neurotrophic factor-mediated Trk receptor signaling
Reactome Frs2-mediated activation
ARMS-mediated activation
NGF-independant TRKA activation
PI3K/AKT activation
WikiPathways MAPK Signaling Pathway
BDNF signaling pathway
Integrated Pancreatic Cancer Pathway
NGF signalling via TRKA from the plasma membrane
References
Ref 548789Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028850)
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.